Simplify Health Care ETF

The Simplify Health Care ETF (PINK) seeks long term capital appreciation by providing investors with multi-cap exposure to groundbreaking and innovative companies in biotech, medtech, gene therapy, and other fast growing health care related sectors. Michael Taylor serves as lead portfolio manager of the ETF and brings over two decades of experience managing long/short health care equity portfolios at leading hedge funds. PINK is the first 100% pro bono ETF focused on the health care sector and net profits will be donated for the benefit of the Susan G. Komen foundation on an annual basis. PINK: Shares for the Cure Find out more. Benefiting Donations$350,000as of 09/01/25

Simplify Health Care ETF trades as PINK on AMEX. The company is classified in Financial Services / Asset Management and reports in USD.

The current profile places the business in Asset Management. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Simplify Health Care ETF can be compared against peers such as ETC Cabana Target Leading Sector Moderate ETF, FlexShares STOXX US ESG Select Index Fund, Alliance Bernstein - AB US High Dividend ETF, ARK Israel Innovative Technology ETF, FT Vest U.S. Equity Max Buffer ETF - March, Invesco S&P SmallCap Health Care ETF.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $146.38M, beta of 0.82, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PINK currently shows total debt of N/A and beta of 0.82. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: N-MFP3 (2026-06-04 00:00:00), 485APOS (2026-06-02 00:00:00), NPORT-P (2026-05-29 00:00:00), NPORT-P (2026-05-29 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.simplify.us/etfs/pink-simplify-health-care-etf

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.